Amplify Weight Loss Drug & Treatment ETF (NYSEARCA:THNR) Trading 0.3% Higher – Here’s Why

Amplify Weight Loss Drug & Treatment ETF (NYSEARCA:THNR)’s share price was up 0.3% during mid-day trading on Monday . The company traded as high as $25.80 and last traded at $25.80. Approximately 980 shares traded hands during trading, a decline of 54% from the average session volume of 2,122 shares. The stock had previously closed at $25.72.

Amplify Weight Loss Drug & Treatment ETF Price Performance

The firm has a market cap of $5.13 million, a P/E ratio of 24.31 and a beta of 0.37. The company’s 50-day simple moving average is $24.98 and its 200 day simple moving average is $25.16.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Amplify Weight Loss Drug & Treatment ETF stock. Cravens & Co Advisors LLC acquired a new stake in shares of Amplify Weight Loss Drug & Treatment ETF (NYSEARCA:THNR) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 15,023 shares of the company’s stock, valued at approximately $390,000. Cravens & Co Advisors LLC owned 10.02% of Amplify Weight Loss Drug & Treatment ETF at the end of the most recent reporting period.

Amplify Weight Loss Drug & Treatment ETF Company Profile

The Amplify Weight Loss Drug & Treatment ETF (THNR) is an exchange-traded fund that is based on the VettaFi Weight Loss Drug index. The fund tracks a modified market cap-weighted index of companies from developed markets that manufacture and enable GLP-1 agonist pharmaceutical businesses. THNR was launched on May 21, 2024 and is issued by Amplify Investments.